Pfizer Inc. and BioNTech SE announced on July 29, 2026, that the European Commission (EC) has granted marketing authorization for their 2026-2027 COVID-19 vaccine formula. The monovalent vaccine targets the XFG variant of the JN.1 lineage and is approved for active immunization against SARS-CoV-2 in individuals aged 6 months and older. This authorization is valid across all 27 European Union Member States, as well as Iceland, Liechtenstein, and Norway, ensuring broad regional access ahead of the upcoming respiratory disease season.

The approval follows a recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA), which stated that targeting the XFG variant would provide the best protection against COVID-19. The EC decision was based on the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation issued on July 23, 2026. The CHMP’s assessment relied on a cumulative body of evidence submitted by Pfizer and BioNTech, including clinical, non-clinical, and real-world data supporting the safety and efficacy of the vaccine.

Immune Response and Variant Coverage

Data indicate that the 2026-2027 vaccine formula induces a strong immune response against contemporary circulating and emerging lineages. The monovalent XFG-adapted vaccine demonstrated efficacy against several key sublineages, as detailed below:

Supply Readiness and Distribution

Pfizer and BioNTech have already initiated manufacturing of the monovalent XFG-adapted COVID-19 vaccine at risk to ensure supply readiness. Shipping is set to begin soon to ensure rapid access for the current season, anticipating increased demand during the respiratory disease season. EU Member States and Norway will be supplied either via the EC contract or according to individual country government policies.

The companies have also submitted data for the updated COVID-19 vaccine to regulatory authorities around the world and are continuing to monitor the evolving epidemiology of COVID-19 to meet global public health needs. More than five billion doses of Pfizer-BioNTech COVID-19 vaccines have been distributed globally since the program's inception.

Technology and Authorization Holder

The COVID-19 vaccines developed by Pfizer and BioNTech are based on BioNTech's proprietary mRNA technology and were developed jointly by both companies. BioNTech serves as the Marketing Authorization Holder for the Pfizer-BioNTech COVID-19 vaccine and its adapted vaccines in the United States, the EU, the United Kingdom, and other countries. BioNTech also holds emergency use authorizations or equivalents in other jurisdictions.

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA in combination with XTANDI for men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in the last quarter of 2026. This regulatory milestone aims to expand the use of the combination therapy to an earlier stage of the disease, potentially offering patients a new option to delay cancer progression.

The application is supported by data from the Phase 3 TALAPRO-3 trial. The study demonstrated that TALZENNA plus XTANDI reduced the risk of radiographic progression or death by 52% compared to placebo plus XTANDI. This benefit was consistent across patients with BRCA and non-BRCA HRR gene alterations. The safety profile observed in the trial was consistent with the known profiles of each agent, with no new safety signals reported.

"For men living with metastatic prostate cancer, intervening during the hormone-sensitive stage represents an important opportunity to delay progression before the disease becomes more difficult to manage," said Jeff Legos, Chief Oncology Officer, Pfizer. He emphasized that the data reinforce the importance of biomarker testing to inform treatment decisions as early as possible.

Key Clinical Trial Data

The TALAPRO-3 trial enrolled 599 patients with mCSPC across sites in the U.S., Canada, Europe, South America, and the Asia-Pacific region. The primary endpoint was investigator-assessed radiographic progression-free survival (rPFS).

TALZENNA plus XTANDI is currently indicated in the U.S. for men with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The combination is approved in more than 60 countries for this indication, with specific approvals varying by region. The European Medicines Agency is also reviewing the use of the combination for HRR gene-mutated mCSPC.